NASDAQ:BCRX BioCryst Pharmaceuticals Q3 2026 Earnings Report $8.40 +0.45 (+5.66%) Closing price 04:00 PM EasternExtended Trading$8.39 -0.01 (-0.12%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast BioCryst Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $0.09Beat/MissN/AOne Year Ago EPSN/ABioCryst Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$165.67 millionBeat/MissN/AYoY Revenue GrowthN/ABioCryst Pharmaceuticals Announcement DetailsQuarterQ3 2026Date11/2/2026TimeBefore Market OpensConference Call DateMonday, November 2, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile BioCryst Pharmaceuticals Earnings HeadlinesBioCryst Pharmaceuticals Forms Scientific Advisory Board as R&D Model EvolvesOctober 5 at 3:49 PM | finance.yahoo.comBioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and GrowthOctober 5 at 7:00 AM | globenewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 7 at 1:00 AM | The Oxford Club (Ad)BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysOctober 2, 2026 | americanbankingnews.comIs BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?September 23, 2026 | insidermonkey.comBioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease DrugsSeptember 17, 2026 | finance.yahoo.comSee More BioCryst Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioCryst Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCryst Pharmaceuticals and other key companies, straight to your email. Email Address About BioCryst PharmaceuticalsBioCryst Pharmaceuticals (NASDAQ:BCRX) is a biotechnology company that discovers, develops and commercializes oral medicines for rare diseases. The company focuses on small-molecule therapies designed to address diseases with significant unmet medical needs, including hereditary angioedema and complement-mediated disorders. BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral plasma kallikrein inhibitor used to prevent attacks of hereditary angioedema in adults and pediatric patients. The company also maintains a research and development pipeline focused on potential treatments for rare diseases, including therapies that target the complement system. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically worked on antiviral and enzyme-targeted medicines. Its research contributed to peramivir, an antiviral later marketed as Rapivab for the treatment of influenza. BioCryst markets its products in the United States and select international markets, while using regional partnerships and distribution arrangements to serve additional geographies. The company is led by President and Chief Executive Officer Jon Stonehouse.View BioCryst Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadPenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the Stakes Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
